B+
Overall grade
B
Financial quality
The sleeper story is KKR's expansion to 19.9% ownership with a specific $200M value creation target - this isn't consulting theater anymore, it's a private equity execution plan with real money behind it. While everyone focuses on the post-cyber sales recovery, the binding constraint is specialty margins getting crushed by value implants growing double-digit while premium grows low single-digit. Most telling management quote: 'We do get better margins on those premium implants versus the value implants' - they're winning market share but at the wrong price points. My view changes if they can quantify the value creation timeline or show premium implant acceleration.
The 30-second version
- SLEEPER STORY: They've quietly shifted from hope to execution on the $200M value creation program
- Post-cyber recovery is real but margin pressure from value implants is the binding constraint
- They stopped talking about specific DSO wins and customer metrics disappeared
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Total Sales | $3.2B (+3.3% YoY) | $3.3B (+5.2% YoY) |
| Non-GAAP EPS | $1.10 vs $1.23 prior year | $1.38 vs $1.22 prior year |
| Non-GAAP Operating Margin | 6.96% (-79 bps YoY) | 7.83% (+19 bps YoY) |
| Global Distribution Sales Growth | Mixed, U.S. dental merch -1.2% | 4.8% total, U.S. dental merch +3.3% |
| Global Specialty Products Growth | 4.2% (3.3% constant currency) | 5.9% (3.9% constant currency) |
| Global Technology Group Growth | 7.4% (6.6% constant currency) | 9.7% (9.0% constant currency) |
| Gross Margin | Lower due to glove pricing + promotions | Down 56 bps YoY but stabilized in U.S. dental |
| Operating Cash Flow | $120M vs $151M prior year | $174M vs $151M prior year |
Accountability tracked
7 new promises made4 narrative shifts flagged6 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →